CervoMed to Participate in Healthcare Conference

BOSTON, Sept. 22, 2026 /CourierPR/ -- CervoMed Inc., a clinical-stage company focused on developing treatments for age-related neurologic disorders, announced today that its management team will participate in a panel discussion and one-on-one meetings at the upcoming 5th Annual ROTH Healthcare Opportunities Conference, which will be held in New York, NY, on Tuesday, September 29, 2026.

The panel discussion will be titled "Frontiers in Neuroscience," and it is scheduled to take place from 10:00 AM to 10:50 AM Eastern Time. This panel will not be webcast, but a recording of the session will be made available following the conference.

CervoMed is developing treatments for age-related brain disorders, with its lead drug candidate, neflamapimod, an oral small molecule that targets critical disease processes underlying degenerative disorders of the brain. Neflamapimod inhibits a key enzyme involved in neuroinflammation and neurodegeneration. The company recently completed a Phase 2b trial for DLB (Dementia with Lewy Bodies), a subtype of dementia that is enriched for patients without Alzheimer's disease co-pathology, and announced alignment with the FDA on a potential registration path for neflamapimod in DLB in November 2025.

Initiation of a Phase 3 trial in DLB is contingent upon establishing a partnership and/or securing additional financing. CervoMed has also completed enrollment in its ongoing Phase 2a clinical trial for nfvPPA (a subtype of frontotemporal disorders), and interim biomarker data is anticipated in the early fourth quarter of 2026. The company is also preparing to initiate the Phase 2a clinical trial for ALS (Amyotrophic Lateral Sclerosis) with neflamapimod in the fourth quarter of 2026.

CervoMed's management team will be available for one-on-one meetings with investors and industry professionals during the conference, where they will discuss the company's progress and future plans. The conference, organized by ROTH Capital Partners, is a significant event for healthcare investors and industry professionals, providing a platform for companies to showcase their latest developments and engage with potential partners and investors.

The company's lead drug candidate, neflamapimod, is a key focus of its research and development efforts. Neflamapimod is designed to target critical disease processes in the brain, specifically neuroinflammation and neurodegeneration, which are key factors in the development and progression of various neurologic disorders. The company's Phase 2b trial for DLB, which was completed in November 2025, demonstrated promising results, with the FDA indicating alignment on a potential registration path for neflamapimod in DLB.

CervoMed's ongoing Phase 2a clinical trial for nfvPPA, a subtype of frontotemporal disorders, is another significant development. The company expects to receive interim biomarker data in the early fourth quarter of 2026, which will provide valuable insights into the efficacy and safety of neflamapimod in this patient population. Additionally, the company is preparing to initiate a Phase 2a clinical trial for ALS, a devastating neurodegenerative disease, with neflamapimod in the fourth quarter of 2026. This trial is critical for advancing the drug's potential to treat ALS, a condition with limited treatment options and a significant unmet medical need.

CervoMed's participation in the ROTH Healthcare Opportunities Conference is a testament to the company's commitment to advancing its drug candidates and engaging with the healthcare community. The company's management team will be available for one-on-one meetings and panel discussions, providing investors and industry professionals with a comprehensive overview of the company's progress and future plans.